These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 38070635)
1. Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients. Rehberger Likozar A; Ugovšek S; Šebeštjen M Eur J Pharmacol; 2024 Jan; 963():176232. PubMed ID: 38070635 [TBL] [Abstract][Full Text] [Related]
2. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study. Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335 [TBL] [Abstract][Full Text] [Related]
3. Predictors of functional and morphological arterial wall properties in coronary artery disease patients with increased lipoprotein (a) levels before and after treatment with proprotein convertase subtilisin-kexin type 9 inhibitors. Likozar AR; Šebeštjen M Cardiovasc Ultrasound; 2023 Aug; 21(1):15. PubMed ID: 37580777 [TBL] [Abstract][Full Text] [Related]
4. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841 [TBL] [Abstract][Full Text] [Related]
5. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353 [TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia. Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088 [TBL] [Abstract][Full Text] [Related]
9. In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction. Lou B; Liu H; Luo Y; Jiang GT; Wu H; Wang C; Wu Y; Zhou B; Yuan Z; She J; Liu J Lipids Health Dis; 2022 Oct; 21(1):105. PubMed ID: 36280861 [TBL] [Abstract][Full Text] [Related]
10. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction. Schwartz GG; Giugliano RP Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614 [TBL] [Abstract][Full Text] [Related]
11. Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis. Nagendra L; Mahajan K; Gupta G; Dutta D Indian Heart J; 2023; 75(6):416-422. PubMed ID: 37777180 [TBL] [Abstract][Full Text] [Related]
12. Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population. Hamamura H; Adachi H; Enomoto M; Fukami A; Nakamura S; Nohara Y; Morikawa N; Sakaue A; Toyomasu K; Yamamoto M; Fukumoto Y J Atheroscler Thromb; 2021 Apr; 28(4):329-337. PubMed ID: 32624555 [TBL] [Abstract][Full Text] [Related]
13. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. Mahmood T; Minnier J; Ito MK; Li QH; Koren A; Kam IW; Fazio S; Shapiro MD Eur J Prev Cardiol; 2021 Jul; 28(8):816-822. PubMed ID: 34298554 [TBL] [Abstract][Full Text] [Related]
14. Effect of Different Types and Dosages of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a) Levels: A Network Meta-analysis. Yu Z; Hu L; Sun C; Wang Z; Zhang X; Wu M; Liu L J Cardiovasc Pharmacol; 2023 Jun; 81(6):445-453. PubMed ID: 36972559 [TBL] [Abstract][Full Text] [Related]
15. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867 [TBL] [Abstract][Full Text] [Related]
16. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors. Julius U; Tselmin S; Schatz U; Fischer S; Bornstein SR Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):45-50. PubMed ID: 30838555 [TBL] [Abstract][Full Text] [Related]